MB Venture Partners

Co-founders Gary Stevenson and Joseph R. “Pitt” Hyde III oversee the firm’s investment activities. The firm’s website identifies them as the founders and presents no additional investment committee structure. Decision-making appears concentrated among the founding partners, consistent with a boutique venture firm model.

The firm has hosted and sponsored the Musculoskeletal New Ventures Conference for more than two decades. This conference serves as a primary origination channel, bringing together early-stage device companies and potential strategic acquirers. The conference’s longevity gives the firm an embedded network within the orthopedic surgery and musculoskeletal disease sub-sector.

Based on available public disclosures, the firm makes direct venture investments into private life science companies. There is no public information indicating participation in fund-of-fund commitments, traditional buyout funds, or public-market strategies. Its activities center on equity stakes in startups developing musculoskeletal solutions.

The firm invests primarily in medical device startups focused on musculoskeletal disease. This includes products and technologies relevant to orthopedic surgery, spine treatment, and related surgical interventions. The portfolio’s acquirer list is composed entirely of orthopedic and musculoskeletal strategics.

The firm states it invests in medical device start-ups at all stages of development, from seed to late-stage venture. This full-stage mandate allows it to back companies from initial product design through expansion and pre-exit growth. No stage-specific fund vehicles have been publicly disclosed.